AU2015271608B9 - Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome - Google Patents

Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome Download PDF

Info

Publication number
AU2015271608B9
AU2015271608B9 AU2015271608A AU2015271608A AU2015271608B9 AU 2015271608 B9 AU2015271608 B9 AU 2015271608B9 AU 2015271608 A AU2015271608 A AU 2015271608A AU 2015271608 A AU2015271608 A AU 2015271608A AU 2015271608 B9 AU2015271608 B9 AU 2015271608B9
Authority
AU
Australia
Prior art keywords
tert
alkyl
benzyl
group
trimethylsilyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015271608A
Other languages
English (en)
Other versions
AU2015271608A1 (en
AU2015271608B2 (en
Inventor
A. M. James SHAPIRO
Lachlan Grant YOUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROTOKINETIX Inc
Original Assignee
Protokinetix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protokinetix Inc filed Critical Protokinetix Inc
Publication of AU2015271608A1 publication Critical patent/AU2015271608A1/en
Publication of AU2015271608B2 publication Critical patent/AU2015271608B2/en
Application granted granted Critical
Publication of AU2015271608B9 publication Critical patent/AU2015271608B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2015271608A 2014-06-04 2015-06-02 Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome Active AU2015271608B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007626P 2014-06-04 2014-06-04
US62/007,626 2014-06-04
PCT/CA2015/050509 WO2015184544A1 (en) 2014-06-04 2015-06-02 Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome

Publications (3)

Publication Number Publication Date
AU2015271608A1 AU2015271608A1 (en) 2017-01-12
AU2015271608B2 AU2015271608B2 (en) 2021-05-27
AU2015271608B9 true AU2015271608B9 (en) 2021-06-17

Family

ID=54765902

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015271608A Active AU2015271608B9 (en) 2014-06-04 2015-06-02 Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome

Country Status (8)

Country Link
US (5) US20150352155A1 (https=)
EP (1) EP3152297A4 (https=)
JP (1) JP6801934B2 (https=)
KR (1) KR102411834B1 (https=)
CN (1) CN106661549B (https=)
AU (1) AU2015271608B9 (https=)
NZ (1) NZ727749A (https=)
WO (1) WO2015184544A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011449A1 (en) 2016-01-27 2017-08-03 Protokinetix Inc. Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells
CA3012837A1 (en) 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
WO2021146812A1 (en) * 2020-01-24 2021-07-29 Protokinetix Inc. Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
WO2021179081A1 (en) * 2020-03-10 2021-09-16 Protokinetix Inc. Use of anti-aging glycopeptides for treatment of dry eye disease, retinal degenerative diseases, or occular inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878851B1 (fr) * 2004-12-02 2007-02-09 Inst Nat Sciences Appliq Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation en cryochirurgie et/ou cryopreservation
FR2900656A1 (fr) * 2006-05-03 2007-11-09 Inst Nat Sciences Appliq Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation notamment pour la preservation de materiaux biologiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Affect of AAGP? on the functionality or transplanted islet cells in a diabetic mouse model", ProtoKinetix, (2007-01), URL: https://web.archive.org/web/20131102204306/ http://protokinetix.com/results/assays/In_V ivo.php, (2015-06-23) *
"ProtoKinetix' AAGPTM Improves Effectiveness of Diabetes Treatment", Business Wire., (2007-05-17), URL: http://www.businesswire.com/news/home/2007-05-17005270/en/ProtoKinetix-AAGP-TM- Improves-Effectiveness-Diabetes-Treatment, (2015-08-07) *
Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule, (2010-03), URL: http://web.archive.org/web/20131102194100/ http://protokinetix.com/pdf/aagp-presentation-m arch-2010.pdf, (2015-08-07) *

Also Published As

Publication number Publication date
EP3152297A1 (en) 2017-04-12
US12521419B2 (en) 2026-01-13
US20210023142A1 (en) 2021-01-28
US20150352155A1 (en) 2015-12-10
US20230414675A1 (en) 2023-12-28
EP3152297A4 (en) 2018-01-31
AU2015271608A1 (en) 2017-01-12
CN106661549A (zh) 2017-05-10
US20260102436A1 (en) 2026-04-16
AU2015271608B2 (en) 2021-05-27
WO2015184544A1 (en) 2015-12-10
US20170360844A1 (en) 2017-12-21
CA2950963A1 (en) 2015-12-10
NZ727749A (en) 2023-04-28
CN106661549B (zh) 2022-02-11
JP6801934B2 (ja) 2020-12-16
JP2017520275A (ja) 2017-07-27
KR102411834B1 (ko) 2022-06-21
KR20170023029A (ko) 2017-03-02

Similar Documents

Publication Publication Date Title
US12521419B2 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
JP2016515571A (ja) 調節性ｔ細胞への分化を誘導し、及び増殖を促進することにより免疫反応を抑制するための医薬組成物
AU2021202310A1 (en) Compositions and methods for treating acute radiation syndrome
US11826387B2 (en) Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells
CA2950963C (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
Park et al. The effect of hydroxyethyl starch as a cryopreservation agent during freezing of mouse pancreatic islets
US20230142705A1 (en) Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
WO2017209270A1 (ja) ２５－ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤
HK1237814B (zh) 抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用
HK1237814A1 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
JP2016138087A (ja) 抗腫瘍剤
JP2016023140A (ja) 制がん剤
JP6887665B2 (ja) 新規免疫抑制剤
KR20130072387A (ko) 면역 억제용 약학적 조성물
JP2021088545A (ja) 環状ペプチド化合物、キヌレニン産生阻害剤及び医薬組成物
Feng et al. PROLONGED SURVIVAL OF ISLETS IN MICE TREATED WITH FLT3 LIGAND AND INTERFERON GAMMA.
DL-Homoser-NHC Refs.
CN103989701A (zh) 聚乙二醇4000或聚乙二醇6000在制备预防或治疗水母毒素心脏毒性药物中的应用

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)